NCT03409198 - Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2018

Primary Completion Date

May 11, 2022

Study Completion Date

May 11, 2022

Conditions

Breast CancerHormone Receptor Positive TumorMetastatic Breast Cancer

Interventions

DRUG

Ipilimumab

Ipilimumab blocks CTLA-4 and may deplete regulatory T cells

DRUG

Nivolumab

Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.

DRUG

Pegylated liposomal doxorubicin

Chemotherapy

DRUG

Cyclophosphamide

Chemotherapy

Trial Locations (6)

1000

Institut Jules Bordet, Brussels

1200

Cliniques universitaires Saint-Luc, Brussels

4011

Stavanger University Hospital, Stavanger

5000

CHU UCL Namur, Namur

Unknown

Soerlandet Hospital HF Kristiansand, Kristiansand

Oslo University Hospital, Oslo